Evidence map›Paper›PMID 37145597›Full record

ArticleJAMA network open2023

Prediagnosis Smoking Cessation and Overall Survival Among Patients With Non-Small Cell Lung Cancer.

Xinan Wang, Christopher W Romero-Gutierrez, Jui Kothari, Andrea Shafer, Yi Li, David C Christiani

Abstract read
In one paragraph

Article in JAMA network open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Long-Term Safety and Management of Adverse Events Associated With Lorlatinib inJournal of the advanced practitioner in oncology · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinan WangDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
Christopher W Romero-GutierrezDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
Jui KothariDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
Andrea ShaferPulmonary and Critical Care Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Yi LiDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor.
David C ChristianiDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.

Funding

The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
New Statistical Methods for Modelling Cancer OutcomesR01CA249096 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Yi Li · 2021 to 2026
$2.5M
Detecting racial disparities in cancer survival by integrating multiple high-dimensional observational studiesR01CA269398 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUHA, SUBHARUP, LI, YI · 2022 to 2025
$1.3M
NCI NIH HHS R01 CA249096NCI NIH HHS R01 CA269398NCI NIH HHS R35 CA197449NCI NIH HHS U01 CA209414
6 · The paper itself

Abstract

Importance: Lung cancer remains the leading cause of cancer-related death globally; non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases, and cigarette smoking is the factor most significantly associated with its risk. However, little is known about the association of years since prediagnosis smoking cessation and cumulative smoking with overall survival (OS) following a lung cancer diagnosis. Objective: To characterize the association of years since smoking cessation before diagnosis and cumulative smoking pack-years with OS in patients with NSCLC in a lung cancer survivor cohort. Design, Setting, and Participants: The cohort study involved patients with NSCLC who were recruited to the Boston Lung Cancer Survival Cohort at Massachusetts General Hospital (Boston, Massachusetts) between 1992 and 2022. Patients' smoking history and baseline clinicopathological characteristics were prospectively collected through questionnaires, and OS following lung cancer diagnosis was regularly updated. Exposures: Duration of smoking cessation before a lung cancer diagnosis. Main Outcomes and Measures: The primary outcome was the association of detailed smoking history with OS following a lung cancer diagnosis. Results: Of 5594 patients with NSCLC (mean [SD] age, 65.6 [10.8] years; 2987 men [53.4%]), 795 (14.2%) were never smokers, 3308 (59.1%) were former smokers, and 1491 (26.7%) were current smokers. Cox regression analysis suggested that former smokers had 26% higher mortality (hazard ratio [HR], 1.26; 95% CI, 1.13-1.40; P < .001) and current smokers had 68% higher mortality (HR, 1.68; 95% CI, 1.50-1.89; P < .001) compared with never smokers. Log2-transformed years since smoking cessation before diagnosis were associated with significantly lower mortality among ever smokers (HR, 0.96; 95% CI, 0.93-0.99; P = .003). Subgroup analysis, stratified by clinical stage at diagnosis, revealed that former and current smokers had even shorter OS among patients with early-stage disease. Conclusions and Relevance: In this cohort study of patients with NSCLC, quitting smoking early was associated with lower mortality following a lung cancer diagnosis, and the association of smoking history with OS may have varied depending on clinical stage at diagnosis, potentially owing to the differing treatment regimens and efficacy associated with smoking exposure following diagnosis. Detailed smoking history collection should be incorporated into future epidemiological and clinical studies to improve lung cancer prognosis and treatment selection.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmoking CessationAgedCohort StudiesHumansMaleProportional Hazards Models

Identifiers

PMID37145597
PMCPMC10163381

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.